Western blot analysis of extracts from various cell lines using Cyclin D2 (D52F9) Rabbit mAb #3741.
Western analysis of extracts from Hela cells that were untreated, treated with doxorubicin (0.5 µM, 24 hours), or with nocodazole (50 ng/ml, 24 hours), using Cyclin A2 (BF683) Mouse mAb.
Confocal immunofluorescent analysis of HeLa cells using Cyclin B1 Antibody (green) and β-Tubulin (9F3) Rabbit mAb (Alexa Fluor® 555 Conjugate) #2116 (red) showing concentrated cyclin B1 staining surrounding mitotic chromatin.
Immunohistochemical analysis of paraffin-embedded human colon carcinoma, using Cyclin D1 (92G2) Rabbit mAb.
Western blot analysis of extracts from various cell lines using Cyclin D2 (D52F9) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using Cyclin D3 (DCS22) Mouse mAb.
Western blot analysis of extracts from various cell types using Cyclin E (HE12) Mouse mAb.
Western blot analysis of extracts from MCF-7, SK-N-MC and HeLa cells, untreated or treated with the proteasome inhibitor MG-132, using Cyclin E2 Antibody.
Western blot analysis of extracts from Jurkat and Raji cells, using Cyclin H Antibody.
After the primary antibody is bound to the target protein, a complex with HRP-linked secondary antibody is formed. The LumiGLO® is added and emits light during enzyme catalyzed decomposition.
Western blot analysis of extracts from various cell types using Cyclin B1 Antibody.
Immunohistochemical analysis of paraffin-embedded Apc (min/+) mouse intestine using Cyclin D1 (92G2) Rabbit mAb.
Immunohistochemical analysis of paraffin-embedded human lung carcinoma, using Cyclin D3 (DCS22) Mouse mAb.
Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using Cyclin D1 (92G2) Rabbit mAb in the presence of control peptide (left) or Cyclin D1 Blocking Peptide #1044 (right).
Western blot analysis of extracts from SK-N-MC, C6 and IMCD3 cells, using Cyclin D3 (DCS22) Mouse mAb.
Immunohistochemical analysis of paraffin-embedded H1975 xenograft, using Cyclin D1 (92G2) Rabbit mAb.
Western blot analysis of extracts from MCF7, L929 and C6 cells, using Cyclin D1 (92G2) Rabbit mAb.
|Cyclin A2 (BF683) Mouse mAb 4656||20 µl||
|Cyclin B1 Antibody 4138||20 µl||
||H M R Hm Mk||55||Rabbit|
|Cyclin D1 (92G2) Rabbit mAb 2978||20 µl||
||H M R||36||Rabbit IgG|
|Cyclin D2 (D52F9) Rabbit mAb 3741||20 µl||
||H M R||31||Rabbit IgG|
|Cyclin D3 (DCS22) Mouse mAb 2936||20 µl||
||H M R||31||Mouse IgG1|
|Cyclin E1 (HE12) Mouse mAb 4129||20 µl||
||H Mk||48||Mouse IgG1|
|Cyclin E2 Antibody 4132||20 µl||
|Cyclin H Antibody 2927||20 µl||
||H M R||36||Rabbit|
|Anti-rabbit IgG, HRP-linked Antibody 7074||100 µl||
|Anti-mouse IgG, HRP-linked Antibody 7076||100 µl||
The Cyclin Antibody Sampler Kit provides an economical means of evaluating the presence of cyclin proteins in cells. The kit contains enough primary and secondary antibodies to perform two western blot experiments with each antibody.
Each antibody in the Cyclin Antibody Sampler Kit detects endogenous levels of its respective target protein and does not cross-react with other cyclin proteins.
Monoclonal antibody is produced by immunizing animals with synthetic peptides corresponding to residues within the carboxy terminus of cyclin D1, the amino terminus of cyclin D2, recombinant human cyclin E1, or cyclin A2. Polyclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues within the carboxy terminus of cyclin H, cyclin E2, or the amino terminus of cyclin B. Polyclonal antibodies are purified by protein A and peptide affinity chromatography.
Control of the cell cycle is regulated by a multitude of cellular events and processes. The cyclin dependent kinases (CDK) regulate many of these pathways and constitute an active complex when associated with their cyclin partners. This activity is controlled primarily by phosphorylation, which determines subcellular localization of the CDK/cyclin complex (1,2). Some phosphorylation events control the function of cytoplasmic retention sequences while other events regulate nuclear localization and export sequence function (3,4). Cyclin and cyclin-dependent kinase inhibitor (CKI) levels are regulated by ubiquitination and degradation via the ubiquitin proteasome pathway (5). A variety of CKI proteins associate with these complexes and modulate access to regulatory domains on cyclins (6). Additional complexity is generated as the controlled protein levels of each cyclin oscillate with the stages of cell cycle. Increased expression of Cyclin D1 is associated with certain types of cancer (7,8) and may associate with TSC2 (tuberin) independent of its Cdk partner (9).
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.